T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

 2017 Dec 18;1(27):2724-2728. doi: 10.1182/bloodadvances.2017010470. eCollection 2017 Dec 26.
Li G1, Waite E2, Wolfson J3.

Author information

1
Department of Pathology and Laboratory Medicine and.
2
Department of Pharmacy, Children's of Alabama, Birmingham, AL; and.
3
Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, AL.

Abstract

A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 JAK3-activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).

PMID:
 
29296924
 
PMCID:
 
PMC5745136
 
DOI:
 
10.1182/bloodadvances.2017010470
Free PMC Article